Potent inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 by photosensitizers compounds
Source abstract
Abstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19) posed a major challenge to the public health. Currently, no proven antiviral treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is available. Here we report compounds pentalysine β-carbonylphthalocyanine zinc (ZnPc5K) and chlorin e6 (ce6) potently inhibited the viral infection and replication in vitro with EC50 values at nanomolar level. These compounds were first identified by screening a panel of photosensitizers for photodynamic viral inactivation. Such viral inactivation strategy is implementable, and has unique advantages, including resistance to virus mutations, affordability compared to the monoclonal antibodies, and lack of long-term toxicity.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (22)
Show source-provided references
1. WHO coronavirus disease (COVID-19) dashboard. 2020.
2. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review10.1001/jama.2020.12839 ↗
3. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes10.1038/s41591-020-0868-6 ↗
4. Enhanced photodynamic efficacy of zinc phthalocyanine by conjugating to heptalysine10.1021/bc3002997 ↗
5. Safety evaluation of an amino acid based photosensitizer (in Chinese)
6. Efficiency and pharmacokinetics of photosense: a new liposomal photosensitizer formulation based on aluminum sulfophthalocyanine10.1007/s11094-005-0150-8 ↗
7. Photocyanine: a novel and effective phthalocyanine-based photosensitizer for cancer treatment10.1142/S1793545820300098 ↗
8. A phase Ι study to evaluate the application of photocyanine using pharmacokinetic and pharmacodynamic analysis in patients with malignancy10.1007/s00280-020-04096-y ↗
9. Summary of color Additives for use in the United States in foods, drugs, cosmetics, and medical devices. 2020.
10. Photodynamic antimicrobial chemotherapy using zinc phthalocyanine derivatives in treatment of bacterial skin infection10.1117/1.JBO.21.1.018001 ↗
11. Pentalysine beta-carbonylphthalocyanine zinc: an effective tumor-targeting photosensitizer for photodynamic therapy10.1002/cmdc.201000042 ↗
12. An effective zinc phthalocyanine derivative for photodynamic antimicrobial chemotherapy10.1016/j.jlumin.2013.10.067 ↗
13. Methylene blue inhibits replication of SARS-CoV-2 in vitro10.1016/j.ijantimicag.2020.106202 ↗
14. Liu
15. Read
16. Photodynamic therapy for COVID-1910.1038/s41566-020-00703-9 ↗
17. COVID-19: beyond the virus. The use of photodynamic therapy for the treatment of infections in the respiratory tract10.1016/j.pdpdt.2020.101804 ↗
18. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies10.1016/j.chom.2021.02.019 ↗
19. Spike mutation D614G alters SARS-CoV-2 fitness10.1038/s41586-020-2895-3 ↗
20. Synthesis and photodynamic activity of a new type of pentalysine 2-carbonylphthalocyanine zinc (in Chinese)
21. A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro10.1371/journal.pcbi.1008489 ↗
22. The time sequences of respiratory and rectal viral shedding in patients with coronavirus disease 201910.1053/j.gastro.2020.05.035 ↗